Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TFPI2 | P48307 | 8/20 | 0.68 |
| ▸ | PPP5C | P53041 | 2/20 | 0.57 |
| ▸ | PPP2CA | P67775 | 1/20 | 0.57 |
| ▸ | NPY4R | P50391 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19341777 | 1.00 | TFPI2 (0.68) | TFPI2PPP5CPPP2CANPY4RALDH1A1 | |
| SCHEMBL2326970 | 1.00 | TFPI2 (0.68) | TFPI2PPP5CPPP2CANPY4RALDH1A1 | |
| SCHEMBL13556913 | 0.88 | ALDH1A1 (0.53) | TFPI2ALDH1A1MEN1TSHRKMT2A | |
| SCHEMBL2331589 | 0.87 | TFPI2 (0.52) | TFPI2ALDH1A1MEN1TSHRKMT2A | |
| SCHEMBL12443568 | 0.85 | TFPI2 (0.50) | TFPI2ALDH1A1MEN1TSHRKMT2A | |
| SCHEMBL9880152 | 0.82 | ALDH1A1 (0.54) | ALDH1A1MEN1TSHRKMT2APOLB | |
| SCHEMBL31195314 | 0.81 | TFPI2 (1.00) | TFPI2PPP5CPPP2CANPY4RTSHR | |
| SCHEMBL1219408 | 0.80 | CYP2C19 (0.67) | TFPI2PPP5CPPP2CANPY4RALDH1A1 | |
| SCHEMBL1219410 | 0.80 | CYP2C19 (0.67) | TFPI2PPP5CPPP2CANPY4RALDH1A1 | |
| SCHEMBL3495133 | 0.79 | SMN1; SMN2 (0.68) | TFPI2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10399993-B2 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| EP-2870161-B1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF REPERFUSION INJURY | LIXTE BIOTECHNOLOGY INC (US) | 2018-08-08 | — | — | EP | disclosed |
| US-10023587-B2 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. (US) | 2018-07-17 | — | — | US | disclosed |
| US-10023587-B2 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. (US) | 2018-07-17 | — | — | US | disclosed |
| EP-2714924-B1 | HDAC Inhibitors for use in the treatment of Gaucher's disease, von Hippel-Lindau disease, phaeochromocytoma and paragangliomas. | LIXTE BIOTECHNOLOGY INC (US) | 2018-03-21 | — | — | EP | disclosed |
| US-20170369503-A1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE | LIXTE BIOTECHNOLOGY, INC. (US) | 2017-12-28 | — | — | US | disclosed |
| US-9833450-B2 | Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disorders | LIXTE BIOTECHNOLOGY, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-9833450-B2 | Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disorders | LIXTE BIOTECHNOLOGY, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-20170340628-A1 | PROTEIN PHOSPHATASE 2A INHIBITORS FOR TREATING MYELODYSPLASTIC SYNDROMES | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2017-11-30 | — | — | US | disclosed |
| US-20170340628-A1 | PROTEIN PHOSPHATASE 2A INHIBITORS FOR TREATING MYELODYSPLASTIC SYNDROMES | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2017-11-30 | — | — | US | disclosed |
| WO-2010014220-A1 | NEUROPROTECTIVE AGENTS FOR THE PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES | LIXTE BIOTECHNOLOGY, INC. (US) | 2010-02-04 | — | — | WO | disclosed |
| US-20100029683-A1 | Methods for regulating cell mitosis by inhibiting serine/threonine phosphateses | LIXTE BIOTECHNOLOGY, INC. | 2010-02-04 | — | — | US | disclosed |
| US-20100029683-A1 | Methods for regulating cell mitosis by inhibiting serine/threonine phosphateses | LIXTE BIOTECHNOLOGY, INC. | 2010-02-04 | — | — | US | disclosed |
| US-20100029640-A1 | Neuroprotective agents for the prevention and treatment of neurodegenerative diseases | LIXTE BIOTECHNOLOGY, INC. | 2010-02-04 | — | — | US | disclosed |
| WO-2009020565-A1 | USE OF PHOSPHATES TO TREAT NEUROBLASTOMAS AND MEDULLOGASTOMAS | LIXTE BIOTECHNOLOGY, INC. (US) | 2009-02-12 | — | — | WO | disclosed |
| US-20090035292-A1 | Use of phosphatases to treat neuroblastomas and medulloblastomas | LIXTE BIOTECHNOLOGY, INC. | 2009-02-05 | — | — | US | disclosed |
| US-20090035292-A1 | Use of phosphatases to treat neuroblastomas and medulloblastomas | LIXTE BIOTECHNOLOGY, INC. | 2009-02-05 | — | — | US | disclosed |
| US-20090036309-A1 | Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. | 2009-02-05 | — | — | US | disclosed |
| US-20090036309-A1 | Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. | 2009-02-05 | — | — | US | disclosed |
| WO-2008097561-A1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE | LIXTE BIOTECHOLOGY HOLDINGS, INC. (US) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029640-A1 | Neuroprotective agents for the prevention and treatment of neurodegenerative diseases | SNCA, NLN, HTT | TFPI2 4324/4885PPP5C 2709/4885PPP2CA 1893/4885 |
| US-20100029683-A1 | Methods for regulating cell mitosis by inhibiting serine/threonine phosphateses | PSPH, PPP5C, BUB1B | TFPI2 2409/4885PPP5C 2/4885PPP2CA 73/4885 |
| US-20090036309-A1 | Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use | HCCS, VHL, OXA1L | TFPI2 4843/4885PPP5C 2860/4885PPP2CA 2048/4885 |
| US-10399993-B2 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | HCCS, OXA1L, OTC | TFPI2 4858/4885PPP5C 3037/4885PPP2CA 2107/4885 |
| US-20170340628-A1 | PROTEIN PHOSPHATASE 2A INHIBITORS FOR TREATING MYELODYSPLASTIC SYNDROMES | PPP2CA, PPP2R2A, PPP3CA | TFPI2 912/4885PPP5C 7/4885PPP2CA 1/4885 |
| US-20170369503-A1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE | HCCS, OXA1L, OTC | TFPI2 4858/4885PPP5C 3037/4885PPP2CA 2107/4885 |
| US-10023587-B2 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | HCCS, OXA1L, OTC | TFPI2 4858/4885PPP5C 3037/4885PPP2CA 2107/4885 |
| US-20090035292-A1 | Use of phosphatases to treat neuroblastomas and medulloblastomas | PPME1, PNKP, PPP6C | TFPI2 4590/4885PPP5C 9/4885PPP2CA 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.